Cagent Vascular Inc spent the week intensifying its focus on Serration Remodeling Therapy, or SRT, for complex peripheral vascular disease and limb salvage. The company used a series of LinkedIn posts and a Charing Cross Symposium presentation to highlight SRT’s ability to deliver controlled luminal gain at low inflation pressures in challenging below‑the‑ankle and pedal anatomy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Several updates pointed to newly published, peer‑reviewed data in the Journal of Endovascular Therapy, described as the largest reported series involving a specialty balloon in inframalleolar and pedal vessels. Reported outcomes included an 89.9% rate of wounds healed or improved at six months, alongside a favorable safety profile that could bolster the technology’s credibility in chronic limb‑threatening ischemia.
Cagent Vascular also spotlighted real‑world #CaseoftheWeek examples, including a complex peroneal‑through‑plantar occlusion treated with the Serranator device in two sizes. These cases emphasized restoration of blood flow to the foot and reinforced messaging around precise device deliverability and procedural control in distal vessels with high risk of limb loss.
At the Charing Cross Symposium 2026, Dr. Frank Arko discussed elastic recoil in peripheral arterial disease and positioned SRT as a potential new standard of care. Data from the PRELUDE‑BTK study showed controlled micro‑fissuring, 21.8% residual stenosis, a 1.9% bailout stent rate, and 97.7% freedom from clinically driven target lesion revascularization at six months, supporting a durability narrative for below‑the‑knee use.
Across its communications, the company framed SRT as offering both clinical and economic advantages by potentially reducing restenosis and repeat procedures. While no new financial or regulatory milestones were disclosed, the combination of peer‑reviewed evidence, physician endorsements, and high‑profile conference exposure appears to strengthen Cagent Vascular’s positioning in limb‑salvage and peripheral vascular markets this week.